Clinical trials: Non Alcoholic Fatty Liver
Steatohepatitis, Nonalcoholic
The COherence of Scatter Identification and Exclusion Algorithm Study
Non-alcoholic fatty liver disease (NAFLD) is currently the most common liver condition worldwide; approximately 55% of the world population will have NAFLD by 2040.
- Trial name
- COSIE (NCT06975579)
- Testing
- Ultrasound image processing
- Where
- United Kingdom
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Institute of Cancer Research, United Kingdom
Non-Alcoholic Fatty Liver Disease, Non Alcoholic Steatohepatitis
NASH-FITTER: Nonalcoholic Steatohepatitis Fitness Intervention Treatment Targeting Endothelial Dysfunction Reversal
This research is being done to find out if aerobic exercise is beneficial in reversing scarring. Physical activity has been shown to increase fitness in healthy individuals as well as in those with NASH.
- Conditions
- Non-Alcoholic Fatty Liver Disease, Non Alcoholic Steatohepatitis, NASH - Nonalcoholic Steatohepatitis
- Trial name
- NASH-FITTER (NCT03864835)
- Testing
- Moderate intensity aerobic exercise
- Sponsor
- Milton S. Hershey Medical Center
Non-Alcoholic Fatty Liver Disease, Obesity, Morbid
Change of Adipose Tissues and Triglyceride After Bariatric Surgery or Life-style Intervention
The study is aimed To quantify the change of adipose tissues, triglyceride in liver and pancreas and cholesterol after lifestyle intervention or bariatric surgery.
- Conditions
- Non-Alcoholic Fatty Liver Disease, Obesity, Morbid, Brown Fat, Metabolic Disease
- Trial name
- NCT03875625
- Testing
- Bariatric surgery, Dietitian led life style modification intervention, Conventional care (control)
- Where
- Hong Kong
- Volunteers
- 80 people
- Sponsor
- Chinese University of Hong Kong
Non-Alcoholic Fatty Liver Disease
High Oral Loading Dose of Cholecalciferol in Non-Alcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) is a metabolic disorder with high prevalence in patients suffering from chronic liver diseases [1].
- Trial name
- NCT05578404
- Testing
- Cholecalciferol
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Tanta University
Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Liver Fibrosis/NASH
Stimulating Fat Tissue Storage With Niacin to Reduce Fat Accumulation in the Liver.
Metabolic dysfunction-associated steatotic liver disease (MASLD) (aka non-alcoholic fatty liver disease), commonly occurring in individuals with obesity and type 2 diabetes can lead to liver inflammation/ fibrosis.
- Conditions
- Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Liver Fibrosis/NASH, Non-Alcoholic Steato-Hepatitis (NASH)
- Trial name
- AGL13 (NCT06843148)
- Testing
- Niacin (250mg)
- Where
- Canada
- Volunteers
- 36 people
- Sponsor
- Université de Sherbrooke
Fatty Liver
Metformin for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD)
The purpose of this study is to find out if Metformin is safe and useful in the treatment of NAFLD.
- Trial name
- NAFLD (NCT00736385)
- Testing
- Glucophage (Metformin)
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Duke University
MASLD, MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)
Accurate Point of Care Liver Disease Diagnostics (Phase 2)
This research study is being conducted to find out more about techniques to non-invasively evaluate liver disease. This is the second phase of a project in which we are testing a new technology to evaluate the liver…
- Conditions
- MASLD, MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease), NAFLD, NAFLD (Nonalcoholic Fatty Liver Disease)
- Trial name
- NCT07518784
- Testing
- LiverScope® exam, MR exam, Blood draw
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of California, San Diego
HIV, Fatty Liver
Raltegravir-based Antiretroviral Versus Maintaining Any Other Antiretroviral Therapy in HIV Mono-infected Patients
People infected with HIV are living longer thanks to the use of antiretroviral therapy (cART). In aging HIV persons, other factors are associated with early death.
- Conditions
- HIV, Fatty Liver, Nonalcoholic Steatohepatitis
- Trial name
- NCT02210715
- Testing
- Isentress., Continue usual antiretroviral therapy
- Where
- Canada
- Volunteers
- 31 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Non-Alcoholic Fatty Liver Disease, Obesity
Influence of the Diversity and Composition of the Microbiota in the Development of Pediatric Fatty Liver
The objectives of the present study are: 1) to identify the intestinal and salivary microbiota associated with the presence and severity of hepatic steatosis in children (Study I: case-control study), and 2) to develop a…
- Conditions
- Non-Alcoholic Fatty Liver Disease, Obesity, Metabolic Syndrome
- Trial name
- MicroKid (NCT04575506)
- Testing
- Multidisciplinary intervention program
- Where
- 2 sites in Spain
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Universidad Pública de Navarra
Obesity, Nonalcoholic Fatty Liver Disease
Fatty Liver Disease in Obese Children
Although weight reduction through physical activity-based interventions is the mainstay therapy for nonalcoholic fatty liver disease (NAFLD), its maintenance is difficult and typically unsuccessful.
- Conditions
- Obesity, Nonalcoholic Fatty Liver Disease, Cardiovascular Disease
- Trial name
- NCT02117700
- Testing
- N-acetyl cysteine 600 mg once/day, N-acetyl cysteine 600mg twice/day
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Nemours Children's Clinic
Insulin Resistance, Prediabetic State
Dexamethasone/Pancreatic Clamp P&F
This is a single-center, prospective, randomized, controlled (crossover) clinical study designed to investigate the specific dose-response impact of insulin infusion rate (IIR) on blood glucose levels during a pancreatic clamp…
- Conditions
- Insulin Resistance, Prediabetic State, Non-Alcoholic Fatty Liver Disease, Overweight and Obesity
- Trial name
- NCT06126354
- Testing
- Insulin human, Octreotide Acetate, Glucagon
- Where
- United States
- Sponsor
- Columbia University
Rheumatoid Arthritis, Non-Alcoholic Steatohepatitis
A Study to Assess the Safety and Tolerability of LB-P6 and LB-P8 in Healthy Participants
The study is designed to assess the safety and tolerability of multiple ascending doses of LB-P6 or LB-P8 in healthy participants.
- Trial name
- NCT05053165
- Testing
- LB-P6, LB-P8
- Where
- Australia
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- LISCure Biosciences
NAFLD
Genetic-specific Effects of Fructose on Liver Lipogenesis
The primary goal of this study is to identify a set of genotypes that increase the risk for nonalcoholic fatty liver disease (NAFLD) and predispose individuals to increased de novo lipogenesis (DNL) and liver fat accumulation…
- Trial name
- NCT03783195
- Testing
- Sugar drink
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis With Liver Fibrosis
Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA)
The study aims to evaluate two, orally administered, investigational agents - PF-06865571 (DGAT2 inhibitor) and the coadministration of PF-06865571 with PF-05221304 (ACC inhibitor).
- Trial name
- MIRNA (NCT04321031)
- Testing
- PF-06865571, PF-05221304
- Where
- 291 sites in United States, Bulgaria and 10 more
- Volunteers
- 256 people
- Sponsor
- Pfizer
Effect of SGLT2 Inhibitors NAFLD in Type 2 Diabetic Patients with Diabetic Nephropathy
Effect of SGLT2 Inhibitors on NAFLD in Type 2 Diabetic Patients with Diabetic Nephropathy
To rule out the beneficial effect of SGLT2-I to reduce liver fat, and change in inflammatory markers (ALT, AST) in type 2 diabetic patients with non-alcoholic fatty liver disease.
- Trial name
- NCT06668753
- Testing
- Dapagliflozin 10mg Tab or Empagliflozin 10 mg Tab
- Volunteers
- 114 people
- Sponsor
- Assiut University
Fatty Liver Disease
A Research Study of a Potential New Medicine (NNC4005-0001) for Liver Disease in Adult Participants With Increased Body Weight and Liver Fat
The purpose of this clinical study is to find out if NNC4005-0001 is well-tolerated and safe for people who have increased body weight and increased liver fat.
- Trial name
- NCT07214870
- Testing
- NNC4005-001
- Where
- Canada
- Volunteers
- 29 people
- Sponsor
- Novo Nordisk A/S
NAFLD, Fatty Liver
A Nutrigenetic Intervention in MASLD
The study is designed as a 12-week randomized controlled dietary intervention in individuals who had been diagnosed with NAFLD in the last 6 months and whose body mass index is above 25 at the time of participation in the…
- Trial name
- NCT06220695
- Testing
- Dietary intervention
- Where
- Turkey (Türkiye)
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Maastricht University
Liver Diseases, Primary Biliary Cirrhosis
Repeatability and Reproducibility of Multiparametric MRI
This study aims to prospectively assess the repeatability and reproducibility of iron-corrected T1 (cT1), T2*, and hepatic proton density fat fraction (PDFF) quantification with multiparametric MRI using the LiverMultiScan™ (LMS…
- Conditions
- Liver Diseases, Primary Biliary Cirrhosis, Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis
- Trial name
- NCT03743272
- Testing
- LiverMultiScan
- Where
- 4 sites in Netherlands, United Kingdom
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Perspectum
Cardiovascular Diseases, Lipid Disorder
SRMA of the Effect of Soy Milk vs Cow's Milk on Cardiometabolic Outcomes
Dairy consumption has shown associations with decreased incidence of cardiometabolic diseases. With the growing interest in plant-based eating, and the mounting evidence for the cardiovascular benefits of plant forward diets…
- Conditions
- Cardiovascular Diseases, Lipid Disorder, Metabolic Disease, Non-Alcoholic Fatty Liver Disease
- Trial name
- NCT05637866
- Testing
- Soy milk
- Where
- Canada
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- University of Toronto
Polycystic Ovary Syndrome (PCOS) With Concurrent Nonalcoholic Fatty Liver Disease (NAFLD)
Evaluation of the Therapeutic Effects of Curcumin on Changes in Lipid, Metabolic, and Hormonal Profiles, Liver Enzyme Activity, and Ultrasonography Morphology of the Liver in Women With Polycystic Ovary Syndrome and Nonalcoholic Fatty Liver Disease: A Double-blind, Placebo-controlled Clinical Trial
Background and Objectives: Polycystic ovary syndrome (PCOS) and nonalcoholic fatty liver disease (NAFLD) commonly co-occur and are associated with insulin resistance, chronic inflammation, and metabolic and hormonal imbalances.
- Trial name
- NCT07278128
- Testing
- Patients (women of reproductive age suffering from non-alcoholic fatty liver with polycystic ovary syndrome) receiving 500 mg curcumin capsules (prepared from the extraction of turmeric in the laborat
- Where
- Iran
- Volunteers
- 74 people
- Sponsor
- Fateme Moshirenia
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.